The effect of high-dose ascorbate supplementation on plasma lipoprotein(a) levels in patients with premature coronary heart disease

A. G. Bostom, A. L. Hume, C. B. Eaton, J. P. Laurino, Lisa Yanek, M. S. Regan, W. H. McQuade, W. Y. Craig, G. Perrone, P. F. Jacques

Research output: Contribution to journalArticle

Abstract

Study Objective. To determine the efficacy of high-dose ascorbate supplementation in lowering lipoprotein(a) [Lp(a)] levels in patients with premature coronary heart disease (CHD). Design. Randomized, double-blind, placebo-controlled trial. Setting. Outpatient clinic. Patients. Forty-four patients with documented premature CHD, defined as confirmed myocardial infarction and/or angiographically determined stenosis of 50% or greater in at least one major coronary artery before age 60 years. Interventions. Patients were block randomized on the basis of age, gender, and screening Lp(a) concentrations to receive ascorbate 4.5 g/day or placebo for 12 weeks. Measurements and Main Results. High-dose ascorbate was well tolerated and produced a marked elevation in mean plasma ascorbate levels (+1.2 mg/dL p

Original languageEnglish (US)
Pages (from-to)458-464
Number of pages7
JournalPharmacotherapy
Volume15
Issue number4
StatePublished - 1995
Externally publishedYes

Fingerprint

Lipoprotein(a)
Coronary Disease
Placebos
Ambulatory Care Facilities
Coronary Vessels
Pathologic Constriction
Myocardial Infarction

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Bostom, A. G., Hume, A. L., Eaton, C. B., Laurino, J. P., Yanek, L., Regan, M. S., ... Jacques, P. F. (1995). The effect of high-dose ascorbate supplementation on plasma lipoprotein(a) levels in patients with premature coronary heart disease. Pharmacotherapy, 15(4), 458-464.

The effect of high-dose ascorbate supplementation on plasma lipoprotein(a) levels in patients with premature coronary heart disease. / Bostom, A. G.; Hume, A. L.; Eaton, C. B.; Laurino, J. P.; Yanek, Lisa; Regan, M. S.; McQuade, W. H.; Craig, W. Y.; Perrone, G.; Jacques, P. F.

In: Pharmacotherapy, Vol. 15, No. 4, 1995, p. 458-464.

Research output: Contribution to journalArticle

Bostom, AG, Hume, AL, Eaton, CB, Laurino, JP, Yanek, L, Regan, MS, McQuade, WH, Craig, WY, Perrone, G & Jacques, PF 1995, 'The effect of high-dose ascorbate supplementation on plasma lipoprotein(a) levels in patients with premature coronary heart disease', Pharmacotherapy, vol. 15, no. 4, pp. 458-464.
Bostom, A. G. ; Hume, A. L. ; Eaton, C. B. ; Laurino, J. P. ; Yanek, Lisa ; Regan, M. S. ; McQuade, W. H. ; Craig, W. Y. ; Perrone, G. ; Jacques, P. F. / The effect of high-dose ascorbate supplementation on plasma lipoprotein(a) levels in patients with premature coronary heart disease. In: Pharmacotherapy. 1995 ; Vol. 15, No. 4. pp. 458-464.
@article{f63d06335fd2469c8eac26aabda20ca5,
title = "The effect of high-dose ascorbate supplementation on plasma lipoprotein(a) levels in patients with premature coronary heart disease",
abstract = "Study Objective. To determine the efficacy of high-dose ascorbate supplementation in lowering lipoprotein(a) [Lp(a)] levels in patients with premature coronary heart disease (CHD). Design. Randomized, double-blind, placebo-controlled trial. Setting. Outpatient clinic. Patients. Forty-four patients with documented premature CHD, defined as confirmed myocardial infarction and/or angiographically determined stenosis of 50{\%} or greater in at least one major coronary artery before age 60 years. Interventions. Patients were block randomized on the basis of age, gender, and screening Lp(a) concentrations to receive ascorbate 4.5 g/day or placebo for 12 weeks. Measurements and Main Results. High-dose ascorbate was well tolerated and produced a marked elevation in mean plasma ascorbate levels (+1.2 mg/dL p",
author = "Bostom, {A. G.} and Hume, {A. L.} and Eaton, {C. B.} and Laurino, {J. P.} and Lisa Yanek and Regan, {M. S.} and McQuade, {W. H.} and Craig, {W. Y.} and G. Perrone and Jacques, {P. F.}",
year = "1995",
language = "English (US)",
volume = "15",
pages = "458--464",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "4",

}

TY - JOUR

T1 - The effect of high-dose ascorbate supplementation on plasma lipoprotein(a) levels in patients with premature coronary heart disease

AU - Bostom, A. G.

AU - Hume, A. L.

AU - Eaton, C. B.

AU - Laurino, J. P.

AU - Yanek, Lisa

AU - Regan, M. S.

AU - McQuade, W. H.

AU - Craig, W. Y.

AU - Perrone, G.

AU - Jacques, P. F.

PY - 1995

Y1 - 1995

N2 - Study Objective. To determine the efficacy of high-dose ascorbate supplementation in lowering lipoprotein(a) [Lp(a)] levels in patients with premature coronary heart disease (CHD). Design. Randomized, double-blind, placebo-controlled trial. Setting. Outpatient clinic. Patients. Forty-four patients with documented premature CHD, defined as confirmed myocardial infarction and/or angiographically determined stenosis of 50% or greater in at least one major coronary artery before age 60 years. Interventions. Patients were block randomized on the basis of age, gender, and screening Lp(a) concentrations to receive ascorbate 4.5 g/day or placebo for 12 weeks. Measurements and Main Results. High-dose ascorbate was well tolerated and produced a marked elevation in mean plasma ascorbate levels (+1.2 mg/dL p

AB - Study Objective. To determine the efficacy of high-dose ascorbate supplementation in lowering lipoprotein(a) [Lp(a)] levels in patients with premature coronary heart disease (CHD). Design. Randomized, double-blind, placebo-controlled trial. Setting. Outpatient clinic. Patients. Forty-four patients with documented premature CHD, defined as confirmed myocardial infarction and/or angiographically determined stenosis of 50% or greater in at least one major coronary artery before age 60 years. Interventions. Patients were block randomized on the basis of age, gender, and screening Lp(a) concentrations to receive ascorbate 4.5 g/day or placebo for 12 weeks. Measurements and Main Results. High-dose ascorbate was well tolerated and produced a marked elevation in mean plasma ascorbate levels (+1.2 mg/dL p

UR - http://www.scopus.com/inward/record.url?scp=0029049412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029049412&partnerID=8YFLogxK

M3 - Article

C2 - 7479198

AN - SCOPUS:0029049412

VL - 15

SP - 458

EP - 464

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 4

ER -